1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Biohaven’s Degrader Moves Ahead But Pivotal Bipolar Results Depress Shares

 
• By Andrew McConaghie

The company has suffered a setback to its neuroscience asset, BHV-7000, and while its autoimmune disease candidate BHV-1300 is progressing, investors have their doubts.

Biohaven

Biohaven has provided mixed updates from its broad and ambitious pipeline, with solid but unspectacular results from its protein degrader candidate, BHV-1300, and a miss from its ion channel activator, BHV-7000, in a registrational Phase II/III study in bipolar depression.

Both drugs are touted as possible blockbusters in their respective therapy areas, with BHV-7000 being seen as potentially its most valuable asset. A selective activator of Kv7.2/Kv7

Key Takeaways
  • Biohaven's BHV-1300 is a potential first-in-class protein degrader in autoimmune disease but investor doubts persist on whether it can compete with FcRn-targeting antibody assets

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 
• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

More from Therapy Areas

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 
• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

Boehringer’s Next Generation IPF Drug Underwhelms

 
• By Andrew McConaghie

The company hoped its follow-up to blockbuster Ofev could clearly improve efficacy and safety benefits, but the full Phase III results from nerandomilast’s FIBRONEER-IPF fall short of a slam dunk.